|
gptkbp:instanceOf
|
gptkb:drug
ACE inhibitor
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C09AA05
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:brand
|
gptkb:Altace
gptkb:Tritace
Ramace
|
|
gptkbp:CASNumber
|
87333-19-5
|
|
gptkbp:category
|
prodrug
antihypertensive agent
carboxamide
lactam
|
|
gptkbp:chemicalFormula
|
C23H32N2O5
|
|
gptkbp:contraindication
|
pregnancy
history of angioedema
|
|
gptkbp:discoveredBy
|
gptkb:Hoechst_AG
|
|
gptkbp:eliminationHalfLife
|
13-17 hours (ramiprilat)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstSynthesized
|
1981
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ramipril
|
|
gptkbp:interactsWith
|
gptkb:NSAIDs
gptkb:aliskiren
lithium
angiotensin II receptor blockers
potassium-sparing diuretics
other ACE inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits angiotensin-converting enzyme
|
|
gptkbp:metabolism
|
gptkb:ramiprilat
|
|
gptkbp:molecularWeight
|
416.51 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
73%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
cough
hyperkalemia
angioedema
|
|
gptkbp:usedFor
|
heart failure
hypertension
prevention of cardiovascular events
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|